Investing.com - Iovance Biotherapeutics (NASDAQ: IOVA) reported second quarter EPS of $-0.34, better than the analyst estimate of $-0.35. Revenue for the quarter came in at $31.11M versus the consensus estimate of $26.46M.
Iovance Biotherapeutics's stock price closed at $7.94. It is down -27.59% in the last 3 months and up 4.47% in the last 12 months.
Iovance Biotherapeutics saw 5 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Iovance Biotherapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Iovance Biotherapeutics's Financial Health score is "weak performance".
Check out Iovance Biotherapeutics's recent earnings performance, and Iovance Biotherapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar